Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine

  1. Xammy Huu Nguyenla
  2. Timothy A. Bates
  3. Mila Trank-Greene
  4. Mastura Wahedi
  5. Fikadu G. Tafesse
  6. Marcel Curlin
Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

As novel SARS-CoV-2 variants continue to emerge, the updated XBB.1.5 monovalent vaccines remain to be evaluated in terms of immunogenicity against live clinical isolates. We report boosting of IgG(2.1X), IgA(1.5X), and total IgG/A/M(1.7X) antibodies targeting the spike receptor-binding domain and neutralizing titers against WA1(2.2X), XBB.1.5(7.4X), EG.5.1(10.5X), and JN.1(4.7X) variants.

Article activity feed

  1. Version published to 10.1101/2024.03.25.24304857v1 on medRxiv